How Nitrosamine Impurities Affect Your Blood Pressure Medicine

How nitrosamine affects blood pressure medicine

Guest Author: Phil Koerner, PhD. The U.S. Food and Drug Administration (USFDA) and The European Medicines Agency (EMA) have set legally-binding limits for nitrosamine impurities in sartan blood pressure medicines. Continue Reading

Powerful Analytical Solutions for Biotherapeutics Development and QC

A look into biotherapeutics development and QC testing in the pharmaceutical industry.

A transformation in the pharmaceutical industry has occurred in the past few decades due to the advancement of biologics as therapeutic agents. What is less often discussed is a similar Continue Reading

LC-MS/MS Method for Determination of NDMA and NDEA in Valsartan

Valsartan

By: Philip J. Koerner, Ph.D. – Global Industry Manager – Pharmaceutical The Korea Food and Drug Administration (KFDA), in cooperation with SCIEX Korea, has recently published an official LC-MS/MS method using Continue Reading